Amalia Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amalia Ruiz has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Giacomo Reina
Empa – Swiss Federal Laboratories for Materials Science and Technology Laboratory For Nanomaterials in Health St. Gallen Switzerland
8 shared publications - Maria Puerto Morales
Instituto de Ciencia de Materiales de Madrid, ICMM/CSIC, C/Sor Juana Inés de la Cruz 3, 28049 Madrid, Spain
6 shared publications - Cristina Martín
Department of Bioengineering, Universidad Carlos III de Madrid, Leganés 28911, Spain
5 shared publications - Jacobo Elies
Institute of Cancer Therapeutics, University of Bradford, Bradford, Richmond Rd, Bradford BD7 1DP, United Kingdom
5 shared publications - Alberto Bianco
CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572 University of Strasbourg, ISIS France
3 shared publications - Klaus Pors
Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, UK
3 shared publications
Latest Publications
- 19 March 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3)
Innovative Nanocarriers of Sorafenib in the Optimisation of Therapeutic Outcome: Challenges and Applications in Breast Cancer
Sorafenib is an oral tyrosine kinase inhibitor which inhibits the growth of cancer cells by inhibiting several tyrosine kinase receptors taking part in the perpetuation and pathogenesis of breast tumours. Sorafenib was approved in 2005 for the treatment of liver and prostate cancers. In recent years, focused studies have explored the drugs clinical potential in breast cancer. There are several clinical trials (ongoing and completed) of sorafenib to treat metastatic breast cancer patients. Interestingly, these have shown encouraging results in particular in combination with other clinically-used drugs. However, effective clinical use has been somewhat hampered due to the drug's hydrophobicity, rapid first pass metabolism, short half-life, low oral bioavailability and side effects including hand and foot reaction as well as hypersensitivity. In attempts to overcome some of these drawbacks, nanotechnology-based delivery systems have been explored including nanocarriers like liposomes, niosomes, lipid-polymer hybrid nanoparticles, solid lipid nanocarriers, microemulsions, nanovectors and gel matrices. We will describe current state-of-the-art nanocarrier-based strategies, and discuss how such approaches can be harnessed to enhance the clinical efficacy of sorafenib for breast cancer treatment.
- 19 March 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3)
Innovative Nanocarriers of Sorafenib in the Optimisation of Therapeutic Outcome: Challenges and Applications in Breast Cancer
Sorafenib is an oral tyrosine kinase inhibitor which inhibits the growth of cancer cells by inhibiting several tyrosine kinase receptors taking part in the perpetuation and pathogenesis of breast tumours. Sorafenib was approved in 2005 for the treatment of liver and prostate cancers. In recent years, focused studies have explored the drugs clinical potential in breast cancer. There are several clinical trials (ongoing and completed) of sorafenib to treat metastatic breast cancer patients. Interestingly, these have shown encouraging results in particular in combination with other clinically-used drugs. However, effective clinical use has been somewhat hampered due to the drug's hydrophobicity, rapid first pass metabolism, short half-life, low oral bioavailability and side effects including hand and foot reaction as well as hypersensitivity. In attempts to overcome some of these drawbacks, nanotechnology-based delivery systems have been explored including nanocarriers like liposomes, niosomes, lipid-polymer hybrid nanoparticles, solid lipid nanocarriers, microemulsions, nanovectors and gel matrices. We will describe current state-of-the-art nanocarrier-based strategies, and discuss how such approaches can be harnessed to enhance the clinical efficacy of sorafenib for breast cancer treatment.
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Smart Materials in Medicine
- Vol. 7, 449-461
Thera-regenerative hydrogel co-loaded with black phosphorus quantum dots and CD44-targeted nanoparticles for metastatic prostate cancer treatment
- 1 January 2026
- Published by KEAI Publishing in Smart Materials in Medicine
- Vol. 7, 449-461
Open AccessThera-regenerative hydrogel co-loaded with black phosphorus quantum dots and CD44-targeted nanoparticles for metastatic prostate cancer treatment
- Open Access
- 15 August 2025
- Published by MDPI AG in Preprints.org
Machine Learning-Driven Drug Repurposing Investigation to Identify New Tubulin Inhibitors Against Cancer
Tubulin is one of the major structural proteins that exists either as free forms or as microtubules. These microtubules have unique characteristics, termed as ‘exquisite dynamic behavior’, that is associated with the polymerization and depolymerization of the microtubules or the tubulin units. In cancer cells, the tubulin-mediated dynamicity is lost owing to the elevated expression and functioning of microtubules. These lead to uncontrolled cancer cell proliferation, evading controlled cell cycle checks, survival, and resistance to existing cancer chemotherapy. Considering this, the tubulins/microtubules are validated drug targets in cancer. The agents targeting the microtubules are called microtubule-targeting agents (MTAs). These agents are further subclassified into three groups and act at 7 druggable sites identified so far. However, the majority of inhibitors approved are phytochemicals and are semisynthetic-derived, which are associated with poor pharmacokinetics and toxicities that hamper their clinical use. The rapidly growing cancer cases globally demands rapid drug discovery. One of the rapid and recommended ways for drug discovery is drug repurposing or repositioning. To achieve this, we employed machine learning (ML)-driven, integrated with in silico-based high-throughput virtual screening of 4500 FDA-approved compounds to identify new tubulin inhibitors interacting with the Colchicine Binding Site (CBS) with anticancer potential. The virtual screening workflow was supported by structure-based drug design approaches including three stages of molecular docking, MM-GBSA binding free energy calculations and molecular dynamics (MD) simulations, leading to a refined library of potential tubulin inhibitors. The best hit compounds were tested biochemically to verify tubulin inhibition, as well as tested against a panel of cancer cell lines, whereby Omeprazole and Podofilox demonstrated promising results. The outcomes of this work may lay a solid foundation for further drug development projects, targeting tubulin and cancer via drug repurposing.
- 15 August 2025
- Published by MDPI AG in Preprints.org
Open AccessMachine Learning-Driven Drug Repurposing Investigation to Identify New Tubulin Inhibitors Against Cancer
Tubulin is one of the major structural proteins that exists either as free forms or as microtubules. These microtubules have unique characteristics, termed as ‘exquisite dynamic behavior’, that is associated with the polymerization and depolymerization of the microtubules or the tubulin units. In cancer cells, the tubulin-mediated dynamicity is lost owing to the elevated expression and functioning of microtubules. These lead to uncontrolled cancer cell proliferation, evading controlled cell cycle checks, survival, and resistance to existing cancer chemotherapy. Considering this, the tubulins/microtubules are validated drug targets in cancer. The agents targeting the microtubules are called microtubule-targeting agents (MTAs). These agents are further subclassified into three groups and act at 7 druggable sites identified so far. However, the majority of inhibitors approved are phytochemicals and are semisynthetic-derived, which are associated with poor pharmacokinetics and toxicities that hamper their clinical use. The rapidly growing cancer cases globally demands rapid drug discovery. One of the rapid and recommended ways for drug discovery is drug repurposing or repositioning. To achieve this, we employed machine learning (ML)-driven, integrated with in silico-based high-throughput virtual screening of 4500 FDA-approved compounds to identify new tubulin inhibitors interacting with the Colchicine Binding Site (CBS) with anticancer potential. The virtual screening workflow was supported by structure-based drug design approaches including three stages of molecular docking, MM-GBSA binding free energy calculations and molecular dynamics (MD) simulations, leading to a refined library of potential tubulin inhibitors. The best hit compounds were tested biochemically to verify tubulin inhibition, as well as tested against a panel of cancer cell lines, whereby Omeprazole and Podofilox demonstrated promising results. The outcomes of this work may lay a solid foundation for further drug development projects, targeting tubulin and cancer via drug repurposing.
- Open Access
- 1 July 2025
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 21 (31) , 6197-6206
Magnetically induced drug release from niosome-based nanocarriers loaded with doxorubicin
Niosomes co-loaded with doxorubicin and magnetic nanoparticles were synthesised using the thin film hydration method. The loading efficiency of the doxorubicin was between 60-70%. The hydrodynamic diameter measured as the average number (mean ± standard deviation), using dynamic light scattering, was found to be 188 ± 68 nm, 141 ± 86 nm and 169 ± 69 nm for the plain niosomes, niosomes loaded with doxorubicin and niosomes loaded with doxorubicin and magnetic nanoparticles, respectively. The zeta potential for all three niosome samples was determined to be -26.4 mV ± 1.9 mV. The thermally mediated release of doxorubicin was monitored using fluorescence spectroscopy and found to follow 1st order kinetics. The rate constant for the thermal release was 1.2x10-6, 1.0x10-4 and 5.1x10-4 min-1 at 298, 313 and 333 K, respectively. The doxorubicin was also released using an alternating magnetic field, this also followed 1st order kinetics and had a rate constant of 1.7x10-2 min-1. This is four orders of magnitude greater than the thermal release at the same temperature (298 K). The work shows the magnetically controlled, burst release from a drug-loaded niosome delivery system. The release was triggered on demand by the application of the alternating magnetic field, resulting in 86% doxorubicin release within 3 hours compared to 3% release in 30 days via thermal release.
- 1 July 2025
- Published by Royal Society of Chemistry (RSC) in Soft Matter
- Vol. 21 (31) , 6197-6206
Open AccessMagnetically induced drug release from niosome-based nanocarriers loaded with doxorubicin
Niosomes co-loaded with doxorubicin and magnetic nanoparticles were synthesised using the thin film hydration method. The loading efficiency of the doxorubicin was between 60-70%. The hydrodynamic diameter measured as the average number (mean ± standard deviation), using dynamic light scattering, was found to be 188 ± 68 nm, 141 ± 86 nm and 169 ± 69 nm for the plain niosomes, niosomes loaded with doxorubicin and niosomes loaded with doxorubicin and magnetic nanoparticles, respectively. The zeta potential for all three niosome samples was determined to be -26.4 mV ± 1.9 mV. The thermally mediated release of doxorubicin was monitored using fluorescence spectroscopy and found to follow 1st order kinetics. The rate constant for the thermal release was 1.2x10-6, 1.0x10-4 and 5.1x10-4 min-1 at 298, 313 and 333 K, respectively. The doxorubicin was also released using an alternating magnetic field, this also followed 1st order kinetics and had a rate constant of 1.7x10-2 min-1. This is four orders of magnitude greater than the thermal release at the same temperature (298 K). The work shows the magnetically controlled, burst release from a drug-loaded niosome delivery system. The release was triggered on demand by the application of the alternating magnetic field, resulting in 86% doxorubicin release within 3 hours compared to 3% release in 30 days via thermal release.
- Open Access
- 24 March 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (4) , 114
Piezoelectric Nanomaterials for Cancer Therapy: Current Research and Future Perspectives on Glioblastoma
Cancer significantly impacts human quality of life and life expectancy, with an estimated 20 million new cases and 10 million cancer-related deaths worldwide every year. Standard treatments including chemotherapy, radiotherapy, and surgical removal, for aggressive cancers, such as glioblastoma, are often ineffective in late stages. Glioblastoma, for example, is known for its poor prognosis post-diagnosis, with a median survival time of approximately 15 months. Novel therapies using local electric fields have shown anti-tumour effects in glioblastoma by disrupting mitotic spindle assembly and inhibiting cell growth. However, constant application poses risks like patient burns. Wireless stimulation via piezoelectric nanomaterials offers a safer alternative, requiring ultrasound activation to induce therapeutic effects, such as altering voltage-gated ion channel conductance by depolarising membrane potentials. This review highlights the piezoelectric mechanism, drug delivery, ion channel activation, and current technologies in cancer therapy, emphasising the need for further research to address limitations like biocompatibility in whole systems. The goal is to underscore these areas to inspire new avenues of research and overcome barriers to developing piezoelectric nanoparticle-based cancer therapies.
- 24 March 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (4) , 114
Open AccessPiezoelectric Nanomaterials for Cancer Therapy: Current Research and Future Perspectives on Glioblastoma
Cancer significantly impacts human quality of life and life expectancy, with an estimated 20 million new cases and 10 million cancer-related deaths worldwide every year. Standard treatments including chemotherapy, radiotherapy, and surgical removal, for aggressive cancers, such as glioblastoma, are often ineffective in late stages. Glioblastoma, for example, is known for its poor prognosis post-diagnosis, with a median survival time of approximately 15 months. Novel therapies using local electric fields have shown anti-tumour effects in glioblastoma by disrupting mitotic spindle assembly and inhibiting cell growth. However, constant application poses risks like patient burns. Wireless stimulation via piezoelectric nanomaterials offers a safer alternative, requiring ultrasound activation to induce therapeutic effects, such as altering voltage-gated ion channel conductance by depolarising membrane potentials. This review highlights the piezoelectric mechanism, drug delivery, ion channel activation, and current technologies in cancer therapy, emphasising the need for further research to address limitations like biocompatibility in whole systems. The goal is to underscore these areas to inspire new avenues of research and overcome barriers to developing piezoelectric nanoparticle-based cancer therapies.
- Open Access
- 8 January 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 249, 114504
CD-44 targeted nanoparticles for combination therapy in an in vitro model of triple-negative breast cancer: Targeting the tumour inside out
- 8 January 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 249, 114504
Open AccessCD-44 targeted nanoparticles for combination therapy in an in vitro model of triple-negative breast cancer: Targeting the tumour inside out
- Open Access
- 1 November 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 102
Engineering PSMA-targeted nanoparticles co-encapsulating mitoxantrone and indocyanine green for precise combinatory therapy in prostate cancer
- 1 November 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 102
Open AccessEngineering PSMA-targeted nanoparticles co-encapsulating mitoxantrone and indocyanine green for precise combinatory therapy in prostate cancer
- Open Access
- 7 June 2024
- Published by American Chemical Society (ACS) in ACS Nanoscience Au
- Vol. 4 (4) , 263-272
Light-Responsive and Antibacterial Graphenic Materials as a Holistic Approach to Tissue Engineering
While the continuous development of advanced bioprinting technologies is under fervent study, enhancing the regenerative potential of hydrogel-based constructs using external stimuli for wound dressing has yet to be tackled. Fibroblasts play a significant role in wound healing and tissue implants at different stages, including extracellular matrix production, collagen synthesis, and wound and tissue remodeling. This study explores the synergistic interplay between photothermal activity and nanomaterial-mediated cell proliferation. The use of different graphene-based materials (GBM) in the development of photoactive bioinks is investigated. In particular, we report the creation of a skin-inspired dressing for wound healing and regenerative medicine. Three distinct GBM, namely, graphene oxide (GO), reduced graphene oxide (rGO), and graphene platelets (GP), were rigorously characterized, and their photothermal capabilities were elucidated. Our investigations revealed that rGO exhibited the highest photothermal efficiency and antibacterial properties when irradiated, even at a concentration as low as 0.05 mg/mL, without compromising human fibroblast viability. Alginate-based bioinks alongside human fibroblasts were employed for the bioprinting with rGO. The scaffold did not affect the survival of fibroblasts for 3 days after bioprinting, as cell viability was not affected. Remarkably, the inclusion of rGO did not compromise the printability of the hydrogel, ensuring the successful fabrication of complex constructs. Furthermore, the presence of rGO in the final scaffold continued to provide the benefits of photothermal antimicrobial therapy without detrimentally affecting fibroblast growth. This outcome underscores the potential of rGO-enhanced hydrogels in tissue engineering and regenerative medicine applications. Our findings hold promise for developing game-changer strategies in 4D bioprinting to create smart and functional tissue constructs with high fibroblast proliferation and promising therapeutic capabilities in drug delivery and bactericidal skin-inspired dressings.
- 7 June 2024
- Published by American Chemical Society (ACS) in ACS Nanoscience Au
- Vol. 4 (4) , 263-272
Open AccessLight-Responsive and Antibacterial Graphenic Materials as a Holistic Approach to Tissue Engineering
While the continuous development of advanced bioprinting technologies is under fervent study, enhancing the regenerative potential of hydrogel-based constructs using external stimuli for wound dressing has yet to be tackled. Fibroblasts play a significant role in wound healing and tissue implants at different stages, including extracellular matrix production, collagen synthesis, and wound and tissue remodeling. This study explores the synergistic interplay between photothermal activity and nanomaterial-mediated cell proliferation. The use of different graphene-based materials (GBM) in the development of photoactive bioinks is investigated. In particular, we report the creation of a skin-inspired dressing for wound healing and regenerative medicine. Three distinct GBM, namely, graphene oxide (GO), reduced graphene oxide (rGO), and graphene platelets (GP), were rigorously characterized, and their photothermal capabilities were elucidated. Our investigations revealed that rGO exhibited the highest photothermal efficiency and antibacterial properties when irradiated, even at a concentration as low as 0.05 mg/mL, without compromising human fibroblast viability. Alginate-based bioinks alongside human fibroblasts were employed for the bioprinting with rGO. The scaffold did not affect the survival of fibroblasts for 3 days after bioprinting, as cell viability was not affected. Remarkably, the inclusion of rGO did not compromise the printability of the hydrogel, ensuring the successful fabrication of complex constructs. Furthermore, the presence of rGO in the final scaffold continued to provide the benefits of photothermal antimicrobial therapy without detrimentally affecting fibroblast growth. This outcome underscores the potential of rGO-enhanced hydrogels in tissue engineering and regenerative medicine applications. Our findings hold promise for developing game-changer strategies in 4D bioprinting to create smart and functional tissue constructs with high fibroblast proliferation and promising therapeutic capabilities in drug delivery and bactericidal skin-inspired dressings.
- Open Access
- 17 May 2024
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 670, 585-598
Oligo(styryl)benzenes liposomal AIE-dots for bioimaging and phototherapy in an in vitro model of prostate cancer
- 17 May 2024
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 670, 585-598
Open AccessOligo(styryl)benzenes liposomal AIE-dots for bioimaging and phototherapy in an in vitro model of prostate cancer
- Open Access
- 8 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 1 (2) , 272-282
Insight into the liposomal encapsulation of mono and bis-naphthalimides
Mitonafide-loaded liposomes are a promising strategy to overcome the neurotoxicity observed in clinical trials for this drug. This study investigates the influence of loaded mitonafide or a dimer analogue on different liposomal formulations and their therapeutic efficacy in vitro. Physicochemical properties of the liposomes were manipulated using different loading methods (namely bilayer or core loading) and varying the rigidity of the bilayer using distinct phospholipid compositions. Our results demonstrated that the mitonafide dimer analogue had a comparable encapsulation efficiency (EE%) into the liposomes when loaded into rigid or flexible bilayers in contrast to the low mitonafide monomer EE%. A pH gradient core loading method resulted in a more efficient mechanism to load the monomer into the liposomes. DOSY NMR and spectrofluorometric studies revealed key differences in the structure of the vesicles and the arrangement of the monomer or the dimer in the bilayer or the core of the liposomes. The in vitro assessment of the formulations using MDA-MB-231 and RT-112 cells revealed that a flexible lipid bilayer allows a faster drug release, which correlated well with the spectroscopy studies. This study investigated for the first time that the characteristics of the lipid bilayer and the loading method influence the encapsulation efficacy, colloidal properties, photoactivity and stability of mono and bis-naphthalimides loaded in a liposomal carrier, essential factors that will impact the performance of the formulation in a biological scenario.
- 8 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 1 (2) , 272-282
Open AccessInsight into the liposomal encapsulation of mono and bis-naphthalimides
Mitonafide-loaded liposomes are a promising strategy to overcome the neurotoxicity observed in clinical trials for this drug. This study investigates the influence of loaded mitonafide or a dimer analogue on different liposomal formulations and their therapeutic efficacy in vitro. Physicochemical properties of the liposomes were manipulated using different loading methods (namely bilayer or core loading) and varying the rigidity of the bilayer using distinct phospholipid compositions. Our results demonstrated that the mitonafide dimer analogue had a comparable encapsulation efficiency (EE%) into the liposomes when loaded into rigid or flexible bilayers in contrast to the low mitonafide monomer EE%. A pH gradient core loading method resulted in a more efficient mechanism to load the monomer into the liposomes. DOSY NMR and spectrofluorometric studies revealed key differences in the structure of the vesicles and the arrangement of the monomer or the dimer in the bilayer or the core of the liposomes. The in vitro assessment of the formulations using MDA-MB-231 and RT-112 cells revealed that a flexible lipid bilayer allows a faster drug release, which correlated well with the spectroscopy studies. This study investigated for the first time that the characteristics of the lipid bilayer and the loading method influence the encapsulation efficacy, colloidal properties, photoactivity and stability of mono and bis-naphthalimides loaded in a liposomal carrier, essential factors that will impact the performance of the formulation in a biological scenario.